Literature DB >> 18162008

Clinical uses of dexmedetomidine in pediatric patients.

Hanna Phan1, Milap C Nahata.   

Abstract

Dexmedetomidine is being used off-label as an adjunctive agent for sedation and analgesia in pediatric patients in the critical care unit and for sedation during non-invasive procedures in radiology. It also has a potential role as part of anesthesia care to prevent emergence delirium and postanesthesia shivering. Dexmedetomidine is currently approved by the US FDA for sedation only in adults undergoing mechanical ventilation for <24 hours. Pediatric experiences in the literature are in the form of small studies and case reports. In patients sedated for mechanical ventilation and/or opioid/benzodiazepine withdrawal, the loading dose ranged from 0.5 to 1 microg/kg and was usually administered over 10 minutes, although not all patients received loading doses. This patient group also received a continuous infusion at rates ranging from 0.2 to 2 microg/kg/h, with higher rates used in burn patients and those with withdrawal following > or =24 hours of opioid/benzodiazepine infusion. The dexmedetomidine dosage used for anesthesia and sedation during non-invasive procedures, such as radiologic studies, ranged from a loading dose of 1-2 microg/kg followed by a continuous infusion at 0.5-1.14 microg/kg/h, with most patients spontaneously breathing. For invasive procedures, such as awake craniotomy or cardiac catheterization, dosage ranged from a loading dose of 0.15 to 1 microg/kg followed by a continuous infusion at 0.1-2 microg/kg/h. Adverse hemodynamic and respiratory effects were minimal; the agent was well tolerated in most patients. The efficacy of dexmedetomidine varied depending on the clinical situation: efficacy was greatest during non-invasive procedures, such as magnetic resonance imaging (MRI), and lowest during invasive procedures, such as cardiac catheterization. Dexmedetomidine may be useful in pediatric patients for sedation in a variety of clinical situations. The literature suggests potential use of dexmedetomidine as an adjunctive agent to other sedatives during mechanical ventilation and opioid/benzodiazepine withdrawal. In addition, because of its minimal respiratory effects, dexmedetomidine has also been used as a single agent for sedation during non-invasive procedures such as MRI. However, additional studies in pediatric patients are warranted to further evaluate its safety and efficacy in all age ranges.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18162008     DOI: 10.2165/00148581-200810010-00006

Source DB:  PubMed          Journal:  Paediatr Drugs        ISSN: 1174-5878            Impact factor:   3.022


  59 in total

Review 1.  Cyclic vomiting syndrome.

Authors:  A M Ravelli
Journal:  J Pediatr Gastroenterol Nutr       Date:  2001       Impact factor: 2.839

2.  Propylene glycol accumulation associated with continuous infusion of lorazepam in pediatric intensive care patients.

Authors:  Michael Chicella; Paul Jansen; Anitha Parthiban; Karen F Marlowe; F Aladar Bencsath; Kem P Krueger; Robert Boerth
Journal:  Crit Care Med       Date:  2002-12       Impact factor: 7.598

3.  Initial experience with dexmedetomidine in paediatric-aged patients.

Authors:  Joseph D Tobias; John W Berkenbosch
Journal:  Paediatr Anaesth       Date:  2002-02       Impact factor: 2.556

4.  The use of dexmedetomidine to facilitate acute discontinuation of opioids after cardiac transplantation in children.

Authors:  Julia C Finkel; Yewande J Johnson; Zenaide M N Quezado
Journal:  Crit Care Med       Date:  2005-09       Impact factor: 7.598

5.  Sedation and analgesia in the pediatric intensive care unit.

Authors:  Joseph D Tobias
Journal:  Pediatr Ann       Date:  2005-08       Impact factor: 1.132

6.  Fatal metabolic acidosis in a pediatric patient receiving an infusion of propofol in the intensive care unit: is there a relationship?

Authors:  R A Strickland; M J Murray
Journal:  Crit Care Med       Date:  1995-02       Impact factor: 7.598

7.  Fatal myocardial failure associated with a propofol infusion in a child.

Authors:  R J Bray
Journal:  Anaesthesia       Date:  1995-01       Impact factor: 6.955

8.  Dexmedetomidine for the treatment of postanesthesia shivering in children.

Authors:  R Blaine Easley; Kenneth M Brady; Joseph D Tobias
Journal:  Paediatr Anaesth       Date:  2007-04       Impact factor: 2.556

9.  Use of dexmedetomidine in children after cardiac and thoracic surgery.

Authors:  Constantinos Chrysostomou; Sylvie Di Filippo; Ana-Maria Manrique; Carol G Schmitt; Richard A Orr; Alfonso Casta; Erin Suchoza; Janine Janosky; Peter J Davis; Ricardo Munoz
Journal:  Pediatr Crit Care Med       Date:  2006-03       Impact factor: 3.624

10.  Metabolic acidosis and fatal myocardial failure after propofol infusion in children: five case reports.

Authors:  T J Parke; J E Stevens; A S Rice; C L Greenaway; R J Bray; P J Smith; C S Waldmann; C Verghese
Journal:  BMJ       Date:  1992-09-12
View more
  34 in total

1.  Discontinuation of prolonged infusions of dexmedetomidine in critically ill children with heart disease.

Authors:  Nelson H Burbano; Andrea V Otero; Donald E Berry; Richard A Orr; Ricardo A Munoz
Journal:  Intensive Care Med       Date:  2011-12-13       Impact factor: 17.440

2.  Dexmedetomidine for transport of a spontaneously breathing combative child.

Authors:  Kevin M Watt; Jason Walgos; Ira M Cheifetz; David A Turner
Journal:  Pediatrics       Date:  2012-08-13       Impact factor: 7.124

3.  Dexmedetomidine in current anaesthesia practice- a review.

Authors:  Shagufta Naaz; Erum Ozair
Journal:  J Clin Diagn Res       Date:  2014-10-20

Review 4.  Alpha-2 adrenergic receptor agonists: a review of current clinical applications.

Authors:  Joseph A Giovannitti; Sean M Thoms; James J Crawford
Journal:  Anesth Prog       Date:  2015

5.  Hemodynamic characteristics of midazolam, propofol, and dexmedetomidine in healthy volunteers.

Authors:  Michael A Frölich; Alireza Arabshahi; Charles Katholi; Jeevan Prasain; Stephen Barnes
Journal:  J Clin Anesth       Date:  2011-05       Impact factor: 9.452

6.  Intranasal Dexmedetomidine as a Sedative for Pediatric Procedural Sedation.

Authors:  Natalie Behrle; Esma Birisci; Jordan Anderson; Sara Schroeder; Abdallah Dalabih
Journal:  J Pediatr Pharmacol Ther       Date:  2017 Jan-Feb

Review 7.  Pharmacologic Considerations for Pediatric Sedation and Anesthesia Outside the Operating Room: A Review for Anesthesia and Non-Anesthesia Providers.

Authors:  Narjeet Khurmi; Perene Patel; Molly Kraus; Terrence Trentman
Journal:  Paediatr Drugs       Date:  2017-10       Impact factor: 3.022

8.  Characterization of dexmedetomidine dosing and safety in neonates and infants.

Authors:  Lauren M Estkowski; Jennifer L Morris; Elizabeth A Sinclair
Journal:  J Pediatr Pharmacol Ther       Date:  2015 Mar-Apr

9.  Update on dexmedetomidine: use in nonintubated patients requiring sedation for surgical procedures.

Authors:  Mohanad Shukry; Jeffrey A Miller
Journal:  Ther Clin Risk Manag       Date:  2010-04-15       Impact factor: 2.423

10.  Comparison of Two Different Intranasal Doses of Dexmedetomidine in Children for Magnetic Resonance Imaging Sedation.

Authors:  Aslihan Tug; Ayse Hanci; Hacer Sebnem Turk; Ferda Aybey; Canan Tulay Isil; Pinar Sayin; Sibel Oba
Journal:  Paediatr Drugs       Date:  2015-12       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.